Author Archives: Scalper1

Apple Music, Pandora Stoke Digital Music In Face Of ‘Value Gap’

Buoyed by Apple ( AAPL ) Music, Spotify and other subscription streaming services, sales of digital music vaulted past physical music sales for the first time in 2015 to become the main revenue stream for recorded music, according to a new industry report released Tuesday. But there’s also a widening “value gap,” as music listening on Alphabet ( GOOGL )-owned video wing YouTube and other free, legal sites don’t bring as much revenue for the industry, the International Federation of the Phonographic Industry trade group said. Digital music sales worldwide contributed 45% of industry revenue in 2015, overtaking the 39% share from sales of CDs and other physical formats, the IFPI’s report said. “After two decades of almost uninterrupted decline, 2015 witnessed key milestones for recorded music: measurable revenue growth globally; consumption of music exploding everywhere; and digital revenues overtaking income from physical formats for the first time,” the IFPI said. The group added that “revenues, vital in funding future investment, are not being fairly returned to rights holders. The value gap is the biggest constraint to revenue growth for artists, record labels and all music rights holders.” Revenue growth came from subscription music streaming services such as Apple Music, Pandora Media ( P ) and Spotify. Others in the subscription sector include Amazon.com ‘s ( AMZN ) Prime Music and Google Play Music. Besides its free YouTube site, Alphabet subsidiary Google in December launched YouTube Red, a video-subscription service that offers ad-free and offline viewing. Music download sales dropped 10.5% in 2015, the report said, while sales of CDs and other physical formats fell 4.5%. The so-called “value gap” arose because some major digital services “are able to circumvent the normal rules that apply to music licensing,” the report said. “User upload services claim they do not need to negotiate licenses for the music available on their platforms, or conclude licenses at artificially low rates, claiming protection from so-called ‘safe harbor’ rules that were introduced in the early days of the Internet and established in both U.S. and European legislation.” IFPI CEO Frances Moore said in a statement that safe harbor rules were designed for the Internet of the past and “should no longer be used to exempt user upload services that distribute music online from the normal conditions of music licensing.” Apple, Alphabet and Amazon stocks were all up a fraction in afternoon trading in the stock market today . Pandora stock was up 2%, near 8. Image provided by Shutterstock .

The S&P 500’s 788,400 Minutes: Measuring A Year-And-A-Half In The Life Of An Index

There may be 525,600 minutes in a normal calendar year. However, there have been 788,400 minutes since the S&P 500 first hit 2050 in November of 2014; there have been 1,314,000 minutes since the NYSE Composite Index rose above the 10,000 level in November of 2013. In other words, lost in the narrative that “there is no alternative,” stocks have not gained significant ground in a very long time. Equally worthy of note, defensive stocks have been far more impressive than their rivals since the S&P 500 first hit 2050 in November of 2014. Consider the PowerShares S&P 500 High Beta Portfolio ETF (NYSEARCA: SPHB ): PowerShares S&P 500 Low Volatility Portfolio ETF (NYSEARCA: SPLV ) price ratio. In a true bullish uptrend, riskier growth-oriented stocks in SPHB outperform less volatile dividend producers in SPLV. As a bull market reaches maturity, that relationship begins to change. SPHB:SPLV begins to wane. There’s another important trend in the relationship between the above-mentioned ETFs. SPHB:SPLV hit a peak in late summer of 2014. The same is true for European stocks via the Vanguard FTSE Europe ETF (NYSEARCA: VGK ), emerging market equities via the Vanguard FTSE Emerging Markets ETF (NYSEARCA: VWO ) as well as high yield bonds via the SPDR Barclays High Yield Bond ETF (NYSEARCA: JNK ). In essence, speculative asset classes all began charting a similar pattern at approximately the same moment in time. Granted, there are plenty of perma-bulls who dismiss the idea that risk assets have anything to worry about. The downward slope of the 200-day moving average on virtually every major stock index and high yield bond index? Technical nonsense. A GAAP P/E ratio of 24 on the S&P 500? Fundamental overvaluation will be remedied in a second-half profit recovery. US corporate debt as a percent of GDP pushing an all-time high, logging similar over-leveraged ratios seen at the top of the tech wreck in 2001 and at the top of the financial crisis in 2008? Low rates make it easy for companies to service their obligations. It is almost as if the excuse-makers willfully ignore lessons in history. The long-term moving averages (200-day) for “risk-off” assets (e.g., treasuries, muni bonds, investment grade bonds, etc.) are sloping upwards, whereas long-term moving averages for “risk-on” assets are sloping downwards. Meanwhile, every reliable measure of S&P 500 valuation – price-to-earnings, price-to-sales, PE10, market-cap-to-GDP, household equity as a percentage of total assets, average investor equity allocation, Tobin’s Q – scream “severely overvalued.” Perhaps most telling of all? The build-up of debt in every nook and cranny of the world’s finances, from households to corporations to governments. Sooner or later, regardless of central bank rate shenanigans, debtors struggle to pay and they go broke. It is true that the S&P 500 as well as the Dow Jones Industrials, while trading at the same place as they traded in November of 2014, went on to set all-time records in May of 2015. Yet that marginally higher milestone only serves to reinforce the corrective activity and volatility that has occurred across all risk assets since May of 2015. Indeed, the high-water mark that the S&P 500 registered 10 1/2 months ago has followed the same path as other risk assets since that all-time pinnacle. Moreover, ten-plus months without a new high has only transpired 11 times in history. In eight of those occurrences? The index succumbed to a bearish top-to-bottom decline of 20%. In fact, even the 2011 euro-zone crisis – a summer of discontent that witnessed a 19%-plus decimation of faith – managed to reclaim new highs well within the 10 month period. No matter how one slices and dices, whether one evaluates risk preferences across asset types or the devastating slide in corporate profits or stall-speed economic growth, the S&P 500 SPDR Trust ETF (NYSEARCA: SPY ) is a low-reward, high-risk prospect in the near-term. Better opportunities will exist when a correction in the large-cap index tracker does not rally back prior to bearish depreciation of 20%, 25%, 30% or more. It is not that I look forward to the inevitable downside to come; rather, I recognize the enormous potential of “buying low” in a new bullish uptrend. Click here for Gary’s latest podcast. Disclosure: Gary Gordon, MS, CFP is the president of Pacific Park Financial, Inc., a Registered Investment Adviser with the SEC. Gary Gordon, Pacific Park Financial, Inc, and/or its clients may hold positions in the ETFs, mutual funds, and/or any investment asset mentioned above. The commentary does not constitute individualized investment advice. The opinions offered herein are not personalized recommendations to buy, sell or hold securities. At times, issuers of exchange-traded products compensate Pacific Park Financial, Inc. or its subsidiaries for advertising at the ETF Expert web site. ETF Expert content is created independently of any advertising relationships.

How Regeneron’s Eylea Growth, Amgen, Sanofi Deal Figure In Stock

Biotech Regeneron Pharmaceuticals ’ ( REGN ) core ophthalmology business still has huge upside as its Eylea sales grow in treating a variety of eye diseases, says RBC Capital. RBC also says that a legal settlement with Amgen ( AMGN ) over Praluent, a drug intended to lower bad LDL cholesterol, would be a positive. Most of Regeneron’s sales come from Eylea, launched in 2011 to treat age-related vision loss in the elderly. Regeneron aims to build sales of Eylea in the market for treating diabetic macular edema (DME), a cause of blindness in working-age people, as well as a related eye disease affecting older people. “Turning DME into a $2 billion to $3 billion market opportunity is important and likely,” Adnan Butt, an RBC Capital analyst, said in a research report Tuesday. In DME, Eylea competes with Roche Holding ’s ( RHHBY ) Lucentis. Regeneron typically reports earnings in early May. Roche, Novartis ( NVS ) and Bayer ( BAYRY ) report earnings on April 19, 21 and 26, respectively, and their commentary could provide insights into Eylea’s growth, says RBC’s Butt. He says that consensus expectations for the recently launched cholesterol drug Praluent, which had only $7 million in December-quarter sales, still need to come down. Amgen makes a rival drug called Repatha. In March, a federal jury upheld the validity of two Amgen patents related to the cholesterol drug, dealing a blow to Regeneron and partner Sanofi ( SNY ). “A settlement with Amgen could be a positive,” Butt said in the report. He rates Regeneron stock outperform, with a price target of 668. Regeneron stock was up more than 1.5% in early afternoon trading in the stock market today , near 402.50. Amgen reports earnings on April 28, followed by Sanofi on April 29. Their earnings calls could provide reads on the status of Praluent litigation, says Butt. Regeneron stock has plunged 26% in 2016 amid a broad sell-off in biotech stocks, including Celgene ( CELG ) and Gilead Sciences ( GILD ). Regeneron shares touched a six-month low below 349 last month but jumped on April 1 after the company announced strong phase three clinical results for dupilumab, a drug for eczema, an itchy skin condition. Regeneron is developing that drug with Sanofi. “The landmark deal with Sanofi provides $160 million per year to fund antibody discovery for eight years, gives Regeneron 50% of the profit and defers all development costs until the partnership is profitable,” added Butts. Startup Intellia Therapeutics late Monday announced a licensing deal with Regeneron. Cambridge, Mass.-based Intellia has developed “gene editing” technology to treat liver and blood diseases. It plans to go public. Regeneron has an IBD composite rating of 58 out of a possible 99, lower than both Celgene and Gilead. IBD’s Medical-Biomed/Biotech group ranks just No. 108 out of 197 industry groups. That’s down from No. 39 six months ago.  But it’s up 9.8% the past four weeks, 10th best in that span. Anika Therapeutics ( ANIK ), Supernus Pharmaceuticals ( SUPN ) and Ligand Pharmaceuticals ( LGND ) have the highest IBD Composite Ratings within the biotech group.